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Chronic fatigue in Hodgkin lymphoma
survivors and associations with anxiety,
depression and comorbidity
L A Daniëls*,1, S Oerlemans2,3, A D G Krol1, C L Creutzberg1 and L V van de Poll-Franse2,3
1Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands; 2Comprehensive Cancer Centre
South, Eindhoven, The Netherlands and 3Center of Research on Psychology in Somatic Diseases (CoRPS), Tilburg University,
Tilburg, The Netherlands
Background: Fatigue is a frequent and persistent problem among Hodgkin lymphoma (HL) survivors. We investigated the
prevalence of clinically relevant fatigue in HL survivors and the relation between fatigue and anxiety and depression.
Methods: Fatigue was measured through the generic European Organization for Research and Treatment of Cancer Quality of
Life Questionnaire (QLQ-C30) and Fatigue Assessment Scale (FAS). Anxiety and depression were measured with the Hospital
Anxiety and Depression Scale. Questionnaires were mailed to 267 HL survivors. Results were compared with a Dutch age-matched
normative population.
Results: Response rate was 68% (median age 46 years, mean time since diagnosis 4.6 years). Prevalence of fatigue was significantly
higher among HL survivors than in the norm population (FAS 41% vs 23%, QLQ-C30 43% vs 28%), as were fatigue levels. There was
a significant association between fatigue, anxiety and depression. Of the HL survivors with high symptom levels of depression,
97% also reported fatigue. In multivariate analysis, depression was strongly associated with high levels of fatigue and, to a lesser
extent, anxiety and comorbidity.
Conclusions: Prevalence rates of fatigue are significantly higher in HL survivors than in the general population and differences are
clinically relevant. Depression and anxiety were strongly associated with high levels of fatigue. Reducing fatigue levels by
treatment of depression and anxiety should be further explored.
Over the past decades, survival of Hodgkin lymphoma (HL)
patients has improved dramatically with 5-year overall survival
rates ranging from 90 to 95% (Engert et al, 2010, 2012). This has
mainly been due to the introduction of multi-agent chemotherapy
and improved radiotherapy techniques. However, with improved
life expectancy, patients often face long-term effects caused by their
treatment, such as treatment-induced secondary tumours or
cardiovascular disease (van Leeuwen et al, 2000; Aleman et al,
2003; De Bruin et al, 2009; van den Belt-Dusebout et al, 2009).
Apart from these adverse physical effects, many HL survivors
also report suffering from long-term psychosomatic and psycho-
social problems (Loge et al, 1997, 2000; Hjermstad et al, 2005;
Mols et al, 2006). A number of studies have focused on these
psychosocial issues in HL survivors, mainly addressing overall
health-related quality of life (HRQoL). A recent review of HRQoL
in HL survivors showed persistent problems in physical, role
physical, social and cognitive functioning (Oerlemans et al, 2011).
These problems were most prevalent in HL patients treated with
combined modality treatment, in women and in patients of older
age. Furthermore, a number of studies have focused specifically on
fatigue, because this is one of the most frequently reported and
most persisting symptoms in HL survivors, and has consistently
been reported to have significant impact on HR-QoL (Fobair et al,
1986; Joly et al, 1996; Flechtner et al, 1998; Loge et al, 1999;
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Ruffer et al, 2003; Hjermstad et al, 2005). The mechanism that
causes fatigue is largely unknown. Associations between fatigue and
clinical or patient characteristics have been made, mainly focusing
on the influence of treatment, time since diagnosis and age.
However, such studies have provided conflicting results (Loge et al,
1999; Ruffer et al, 2003; Hjermstad et al, 2005; Ng et al, 2005;
Heutte et al, 2009). The impact of comorbid conditions, whether or
not caused by cancer treatment, on perceived fatigue has been
studied less frequently. All conducted studies reported increased
fatigue in HL survivors with comorbidities (Knobel et al, 2001; Ng
et al, 2005; Miltenyi et al, 2010). Of these studies, only Ng et al
(2005) compared their results with a norm population consisting of
a group of siblings. Fatigue in the HL survivors was more frequent
and was associated with the presence of cardiac disease.
Fatigue is reported to be a frequent symptom of depression. Few
studies have explored the relationship between fatigue and
depression in HL survivors. Loge et al (2000) reported increased
levels of psychological distress in nearly 50% of fatigued HL
survivors; however, no comparison with a norm population was
made. Ng et al (2005) found that having a psychiatric condition
was a significant variable for increased fatigue. Because of high
prevalence rates of fatigue in the general population, results on
fatigue surveys of cancer survivors should be interpreted with
caution and be compared with an age- and sex-matched norm
population.
The purpose of this study was to investigate the prevalence of
clinically relevant fatigue in HL survivors in The Netherlands
compared with an age- and sex-matched Dutch population, and to
determine the relationship between fatigue and depression, and
other comorbid conditions.
MATERIALS AND METHODS
HL survivors. A cross-sectional survey was conducted at the
Eindhoven Cancer Registry (ECR) among HL survivors. The ECR
records data on all newly diagnosed cancers in the southern part of
the Netherlands, an area with 2.3 million inhabitants, 18 hospital
locations and 2 large radiotherapy institutes. The ECR was used to
select all patients who were diagnosed with HL between 1 January
1999 and 1 December 2010. Deceased patients were excluded by
linking the ECR database with the Central Bureau for Genealogy.
Hodgkin lymphoma survivors were contacted by mail through
their physicians and were asked to participate in this cross-
sectional study by completing and returning a set of question-
naires. In May 2009, patients between 6 months and 10 years after
diagnosis received the first questionnaire. In November 2009,
patients diagnosed between May 2008 and May 2009 were invited
to participate, and in May 2011, patients diagnosed between May
2009 and December 2010 were invited. Ethical approval for this
study was obtained from the University of Tilburg-certified
Medical Ethics Committee.
Questionnaires. Survivors of HL were asked to complete the
validated Dutch version of the European Organization for Research
and Treatment of Cancer Quality of Life Questionnaire (EORTC
QLQ-C30). The QLQ-C30 measures cancer-specific HRQoL and
contains five functional scales (physical, cognitive, emotional,
social and role functioning), a global health status/QoL scale, six
single items assessing additional symptoms and three symptom
scales (pain, fatigue and nausea/vomiting). For all items, Likert-
type response scales are used, with total scores per item ranging
from 4 to 7 points. All subscales and individual item responses are
linearly converted to 0–100 scales (Aaronson et al, 1993). As a
cut-off value for fatigue caseness, we defined a score 423.9 for
the EORTC QLQ-C30 (Cocks et al, 2011), although the fatigue
symptom subscale has not been validated as a stand-alone measure
for fatigue. For partially incomplete questionnaires, imputation of
the mean was used for scales containing at least 50% of the scores
(http://groups.eortc.be/qol/).
Fatigue was also measured with the Fatigue Assessment Scale
(FAS), a validated 10-item questionnaire reflecting mental and
physical fatigue (Michielsen et al, 2003, 2005). Total scores range
from 10 to 50, with a higher score reflecting a higher level of
fatigue. A score over 21 points indicates probable caseness of
fatigue (Michielsen et al, 2003).
Anxiety and depression were measured using the Hospital
Anxiety and Depression Scale (HADS; Zigmond and Snaith, 1983;
Snaith and Zigmond, 1986), which measures levels of symptoms of
anxiety and depression in two subscales of seven items each. A
score 48 on either subscale indicates a possible caseness for an
anxiety or depressive disorder; a score 411 indicates a probable
caseness. For HADS, a score 48 on either subscale was used as a
cut-off value for defining caseness of anxiety or depression, as this
score achieves an optimal balance between sensitivity and
specificity (Zigmond and Snaith, 1983; Snaith and Zigmond,
1986; Bjelland et al, 2002).
Comorbidity was evaluated by the Self-administered Comor-
bidity Questionnaire (Sangha et al, 2003). Education and marital
status were also recorded in the questionnaire. Information on
tumour and treatment characteristics was available from the ECR.
Norm population. The norm population was selected from a
reference cohort of B2200 individuals from the general
Dutch population (CentER panel; van de Poll-Franse et al,
2011b). The set of questionnaires completed for this study
included the QLQ-C30, FAS and HADS questionnaires, and also
data on socio-demographics and comorbid conditions were
provided. To compare the results with that of the HL survivor
cohort, we made an age- and sex-matched selection from this
normative population. This reference cohort is representative for
the Dutch-speaking population in the Netherlands (van de Poll-
Franse LV et al, 2011a, b).
Statistical analysis. All statistical analyses were performed using
SPSS version 20 (SPSS Inc., Chicago, IL, USA). Patient, tumour
and treatment characteristics between respondents, non-respon-
dents and patients with unverifiable addresses were compared
using t-test (numerical variables) and w2-test (categorical vari-
ables). A two-sided P-valueo0.05 was considered statistically
significant.
Differences between fatigue caseness from the EORTC
QLQ-C30 and FAS, and/or caseness of anxiety or depression from
the HADS in HL survivors and the norm population, were
calculated by w2-tests.
Mean fatigue scores from the EORTC QLQ-C30 and FAS were
compared between HL survivors and the norm population using
independent sample t-tests. Clinical relevance of the differences
was defined according to guidelines for the interpretation of the
EORTC QLQ-C30 (Cocks et al, 2011) and according to Norman’s
rule of thumb for the FAS, indicating a ±0.5 s.d. difference of the
norm in scores as a discriminating change (Norman et al, 2003).
Multivariate logistic regression analyses using the dichotomous
FAS score were performed to analyse the association of socio-
demographic, tumour, treatment and comorbidity variables and
fatigue. Variables were included into the model in separate steps.
Demographic variables were added first, then clinical variables and,
third, psychological distress. A two-sided P-valueo0.05 was
considered statistically significant.
RESULTS
Characteristics of the respondents and non-respondents. In
total, 180 (68%) of the 267 HL survivors completed and returned
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the questionnaires. Missing items on the completed questionnaires
were o3% (n¼ 17). Responders were more often male and older
than non-responders and those with unverifiable addresses
(Table 1). Mean time since diagnosis was 4.6 years, mean age at
the time of survey among HL responders was 46 years and 55%
had received combined modality treatment. Only 3% had been
treated with radiotherapy alone. There were no statistically
significant differences between HL responders and the norm
population concerning marital status or education (Table 2). With
regards to comorbidities, HL responders less often reported
hypertension (9% vs 20%) but more often thyroid disease (9% vs
5%) and depression (11% vs 3%) than the norm population.
Fatigue prevalence and symptoms of anxiety and depression.
There were significantly more persons with fatigue among the HL
survivors compared with the norm population (Figure 1 and
Table 3). The QLQ-C30 fatigue subscale identified a 43%
prevalence of fatigue among the HL survivors vs 28% in the norm
population (P¼ 0.002). The FAS questionnaire showed fatigue
prevalence rates of 41% and of 23%, respectively (Po0.001).
Identification of fatigue cases was consistent between the QLQ-C30
and the FAS questionnaire in 83% of the HL survivors and in 81%
of the norm population. Among the HL patients, 23% had high
symptom levels of anxiety and 18% of depression, compared with
13% and 12% in the norm population, respectively.
Of all responding HL survivors, 20% were identified both as a
fatigue case and an anxiety case; 17% were both fatigued and had
symptoms of depression. These numbers were significantly lower
in the norm population (8%, Po0.001, and 9%, P¼ 0.004,
respectively; Figure 1). The prevalence of fatigue among HL
survivors with a high symptom level of depression was 97%
compared with 76% in the norm population.
Similar relationships were found for cognitive functioning
(impairment of concentration and memory) and fatigue, with
significantly lower social functioning and especially lower cognitive
functioning among HL survivors compared with the norm
population (Table 3). There was a clear association between
fatigue and cognitive impairment. The mean scores of cognitive
function were lower among fatigued HL survivors and fatigued
participants of the norm population (74.5 and 86.4 points,
respectively) than in the non-fatigued participants (HL survivors
95.7 and norm population 98 points). Differences are clinically
relevant in both groups, and reflect a large difference in the HL
survivors group and a medium difference in the norm population.
Clinical relevance of fatigue scores. Fatigue scores were sig-
nificantly higher among HL survivors than in the norm
population, and these differences were clinically relevant
(Table 3). Mean QLQ-C30 fatigue scores differed 9.8 points (28.7
vs 18.9), reflecting a small but clinically relevant difference. The
FAS total fatigue scores were 21.4 vs 18.4 points (40.5 s.d.), which
also reflects a clinically relevant (albeit small) difference.
Association of fatigue with patient and treatment factors and
comorbid conditions. Multivariate regression analysis using the
FAS scores showed that a lower level of education was associated
with a higher risk of fatigue (Table 4). After adding clinical
variables to the regression analysis, the significance of level of
education disappeared, and having one to two comorbid condi-
tions (OR 4.7) or 42 comorbid conditions (OR 17.5) were
significantly associated with fatigue.
After adding psychological distress symptoms, however, the
influence of comorbidities lacked statistical significance. Symptoms
of depression (OR 1.8) and anxiety (OR 1.2) were the only factors
significantly associated with high levels of fatigue.
Table 1. Patient and treatment characteristics of the HL survivor cohort
HL responders Non-responders Unverifiable address
N % N % N % P-value
Total 180 35 52
Mean age at time of survey in years (s.d.) 46 (15.6) 40 (13.6) 40 (13.9) 0.01
Range 19–84 21–79 20–83
o40 75 41 18 51 34 65 0.02
40–60 70 39 14 40 14 27
460 35 19 3 9 4 8
Mean time since diagnosis in years (s.d.) 4.6 (2.9) 5.9 (3.2) 4.6 (3.0) 0.07
o5 102 57 14 40 29 56 0.11
5–10 76 42 19 54 23 44
410 2 1 2 6 0
Sex 0.06
Male 99 55 23 66 37 72
Female 81 45 12 34 14 28
Stage at diagnosis 0.60
I 31 17 7 20 9 17
II 94 52 14 40 19 37
III 26 15 6 17 12 23
IV 18 10 4 12 6 12
Treatment 0.50
RT 6 3 0 1 2
CT 74 41 18 51 25 48
RTþCT 99 55 16 46 23 44
Abbreviations: CT¼ chemotherapy only; HL¼Hodgkin lymphoma; RT¼ radiotherapy only; RTþCT¼ radiotherapy and chemotherapy.
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Logistic regression analysis of the QLQ-C30 fatigue data did not
differ from the FAS data (data not shown). Using the QLQ-C30
having one to two comorbidities (OR, 3.0; 95% CI, 1.3–7.3;
P¼ 0.02) and symptoms of depression (OR, 1.2; 95% CI, 1.1–1.4;
P¼ 0.04) were the only variables associated with fatigue.
DISCUSSION
In this cross-sectional study, we found a higher prevalence rate of
fatigue in HL survivors compared with an age- and sex-matched
Dutch normative population of 15% and 18% using two different
validated fatigue measures (QLQ-C30 fatigue and FAS, respec-
tively). We also observed a significant association between fatigue
caseness and high levels of depression and anxiety, especially in the
HL cohort. Mean fatigue levels were significantly increased in the
HL survivors compared with the norm population, and differences
were also found to be clinically relevant. Symptoms of depression,
and (to a lesser extent) anxiety and comorbidities, were found to be
the only variables associated with long-lasting fatigue.
One of the strengths of our study is that we measured fatigue
through both a generic (QLQ-C30) and a fatigue-specific (FAS)
questionnaire. Both questionnaires independently measured a
significantly higher prevalence of fatigue in the HL survivors. We
showed that the identification of fatigue cases between both
questionnaires was consistent in 83% of the HL survivors and 81%
of the norm population. Our data are robust, as missing items
were o3%.
Our study not only shows that HL survivors more often suffer
from chronic fatigue but also clearly shows an association between
fatigue and depression or anxiety. We showed that a combination
of both fatigue and anxiety occurred in 20% of all HL survivors and
of fatigue and depression in 17%, compared with 8% and 9%,
respectively, in the norm population. This significant association
between fatigue and anxiety and depression has also been described
by Loge et al (2000). They reported high HADS scores (anxiety and
depression combined) in 52% of 109 fatigued HL survivors. Their
results, however, were not compared with a control group or with a
norm population. Our study further showed that almost all (97%)
HL survivors with symptoms of depression were also fatigued. As
both studies were cross-sectional by design, it is difficult to evaluate
whether fatigue and anxiety or depression are two separate entities
both occurring more often in HL survivors, or whether fatigue is a
consequence of these psychological conditions. The lower level of
cognitive functioning that we observed among the HL survivors,
reflected in symptoms such as loss of concentration, might be
explained as a manifestation of the impact of fatigue and/or
psychological distress. In our multivariate analysis, we showed that
depression and, to a lesser extent, anxiety were significantly associated
with fatigue. However, due to the design of our study, a causal relation
between fatigue, anxiety and depression cannot be established.
In daily practice, fatigue in HL survivors has proven to be a
prominent problem. Many survivors report to suffer from chronic
fatigue, with often significant impact on daily activities, which has
proven extremely difficult to treat. Studies evaluating interventions
aimed at improvement of fatigue in cancer survivors have often
shown improvement in physical endurance, but limited improve-
ment in the subjective feeling of fatigue and lack of energy
(De Backer et al, 2008). Two recent meta-analyses concluded that
exercise interventions in fatigued cancer patients had a near-
moderate effect size in reducing fatigue at best (Kangas et al, 2008;
Cramp and Byron-Daniel, 2012). Increased awareness of fatigue
and of depression and anxiety among treating physicians is





N % N % P-value
Total 180 327
Mean age at survey in
years (s.d.)
46.1 (15.6) 48.8 (15.7) 0.90
Range 19–84 20–85
o40 75 42 117 36 0.28
40–60 70 39 129 39
460 35 19 81 25
Sex 0.43
Male 99 55 168 51
Female 81 45 159 49
Self-reported comorbidity
Cardiac 17 9.4 21 6.4 0.07
Stroke 2 1.1 1 0.3 0.16
Hypertension 16 8.9 65 19.9 0.01
COPD 19 10.6 41 12.5 0.92
Diabetes mellitus 8 4.4 25 7.6 0.39
Anaemia 4 2.2 14 4.3 0.44
Thyroid disease 17 9.4 16 4.9 0.008
Depression 19 10.6 11 3.4 o0.001
Comorbidity conditions 0.37
No comorbidity 87 48 149 46
p2 Comorbidities 63 35 134 41
42 Comorbidities 21 12 44 13
Marital status 0.62
Partner 133 74 252 77
No partner 44 24 75 23
Education level 0.10
Low 14 8 13 4
Medium 107 59 191 58
High 56 31 122 37






































































Figure 1. Prevalence of caseness of fatigue. Prevalence of caseness of
fatigue according to fatigue subscale of the EORTC QlQ-C30 and FAS,
and caseness of anxiety or depression according to the HADS scale for
both HL survivors and the age-matched Dutch population. The two last
columns describe the prevalence of combined fatigue and anxiety or
depression among all HL survivors and of the norm population.
*Po0.05; **Po0.001.
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Table 3. QLQ-C30, FAS and HADS mean scores for HL survivors vs norm population
HL Norm








Role functioning 83.8 24.4 89.6 20.0 0.05 Trivial
Physical functioning 87.1 15.7 90.9 14.8 0.08 Trivial
Cognitive functioning 82.5 22.0 92.5 15.7 o0.001 Medium
Emotional functioning 82.4 22.9 87.9 17.8 0.03 Small
Social functioning 86.4 22.2 92.8 17.6 o0.001 Small
Symptom scales
Fatigue 28.7 26.4 18.9 20.4 o0.001 Small
Pain 13.0 22.4 14.2 20.9 ¼0.54 Trivial
Nausea/vomiting 3.3 9.2 2.6 9.9 ¼0.45 Trivial
Global Health Status 76.8 18.5 77.7 16.9 ¼0.57 Trivial
FAS
Total fatigue score 21.4 7.6 18.4 5.8 o0.001 Yes
HADS
Anxiety mean scores 4.7 4.2 3.8 4.3 o0.001 No
Anxiety mean score in fatigue cases 7.6 4.5 6.5 4.0 0.31 No
Depression mean scores 3.7 3.8 3.4 3.2 0.02 No
Depression mean score in fatigue cases 6.6 4.1 6.4 4.0 0.83 No
Abbreviations: EORTC QLQ-C30¼European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core-30; FAS¼ Fatigue Assessment Scale; HADS¼Hospital
Anxiety and Depression Scale; HL¼Hodgkin’s lymphoma.
Table 4. Logistic model of factors associated with fatigue using the FAS TOTAL score
Model: block 1 Model: block 1þ2 Model: block 1þ2þ3
Variables OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value
Block 1: Demographic variables
Age 0.99 0.97–1.02 0.64 0.97 0.95–1.01 0.09 0.97 0.94–1.02 0.19
Male vs female 1.42 0.74–2.73 0.29 1.33 0.64–2.76 0.43 2.1 0.79–5.70 0.13
Education: low vs mid 0.22 0.05–0.92 0.038 0.27 0.05–1.37 0.11 0.78 0.06–8.93 0.84
Low vs high 0.14 0.03–0.65 0.12 0.29 0.05–1.65 0.16 1.38 0.10–18.72 0.80
Partner 0.51 0.24–1.08 0.08 0.54 0.24–1.25 0.15 0.41 0.13–1.24 0.12
Block 2: Clinical variables
Time since diagnosis 0.97 0.86–1.11 0.73 0.96 0.81–1.15 0.70
No comorbidity vs 1–2 4.73 2.10–10.64 o0.001 2.76 0.93–8.12 0.06
No comorbidity vs 42 17.49 4.27–71.51 o0.001 4.25 0.68–26.39 0.12
Treatment: CT vs RT 0.69 0.77–6.09 0.73 1.22 0.09–16.03 0.88
Treatment: CT vs CMT 0.85 0.41–1.77 0.68 1.09 0.41–2.93 0.86
Block 3: Psychological variables
HADS anxiety 1.19 1.00–1.41 0.46
HADS depression 1.80 1.37–2.37 o0.001
Abbreviations: CI¼ confidence interval; CMT¼ combined modality treatment; CT¼ chemotherapy; FAS¼ Fatigue Assessment Scale; HADS¼Hospital Anxiety and Depression Scale;
OR¼odds ratio; RT¼ radiotherapy. Bold entries are the values from regression analysis reflecting statistically significant values.
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essential. However, fatigue is more common and need not be a
symptom of depression or anxiety. Differentiating between these
symptoms can be challenging in the clinical setting. A possible aid
in defining depression could be to shift the focus from fatigue to
other dimensions of depression. Symptoms of depression and
anxiety could be amenable to treatment. Psychosocial therapies
such as cognitive behavioural therapy or educational counselling
have proven to be beneficial in reducing symptoms of anxiety and
depression (Kangas et al, 2008).
It might be beneficial for both patients suffering from fatigue
and for patients with depression or anxiety to receive treatment by
professionals, although through different methods of focused
psychosocial support or specific coping strategies, which might
result in a clinically meaningful reduction of fatigue. This
approach, however, should be explored in future studies. Ideally,
HL survivors suffering from chronic fatigue should be invited for a
diagnostic interview to distinguish between fatigue and depression,
and then randomly assigned to specific psychosocial therapies. As
HL survivors are at risk for a variety of comorbid conditions due to
late treatment sequelae, such as cardiovascular diseases (Aleman
et al, 2003; van den Belt-Dusebout et al, 2007), which could
predispose for higher levels of fatigue, we examined the possible
association of fatigue and comorbid conditions. Hodgkin lym-
phoma survivors self-reported depression more frequently than the
norm population. Our multivariate analysis showed a trend for the
association between self-reported comorbidities and fatigue.
However, mean time since diagnosis and treatment in this survey
was still relatively short (mean 4.6 years, range 6–122 months),
which means that the majority of the cohort is not yet at risk for
late treatment sequelae. Moreover, with a mean age of 46 years, a
large part of both the cohort and the norm population would not
yet suffer from serious comorbidities.
Rates of fatigue in HL survivors in this study (43% by using
QLQ-C30 and 41% by using FAS) are slightly higher than the rates
reported by others (Loge et al, 1999; Knobel et al, 2001; Hjermstad
et al, 2005). These three studies reported fatigue rates of 26–30% in
HL survivors, but all used the same HL cohort. More recent data
on cancer-related fatigue in patients with other types of cancer
using the EORTC QLQ-C30 and Multidimensional Fatigue
Inventory showed prevalence rates of 36–48%, which are
comparable to our results (Cella et al, 2001; Kuhnt et al, 2009;
Schultz et al, 2011; Berger et al, 2012).
In conclusion, our results show a clinically relevant higher
prevalence rate of fatigue in HL survivors when compared with an
age- and sex-matched population. We also found a significant
association between fatigue and anxiety or depression. The only
factors significantly associated with high levels of fatigue were
symptoms of depression and anxiety. This might have implications
for the diagnosis and treatment of fatigue in the clinical setting, as
psychosocial therapies have proven to be effective in reducing anxiety
and depression, and could therefore be beneficial in reducing levels of
fatigue as well. This should be further examined in future trials.
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